Muhammad Hassan Waseem

Muhammad Hassan Waseem

Auto-generated profile, based on publicly available information

Muhammad Hassan Waseem

Allama Iqbal Medical College

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
ASAreeba Shoaib
Areeba Shoaib
NRNohela Rehman
Nohela Rehman
MOMuhammad Osama
Muhammad Osama
PTPawan Kumar Thada
Pawan Kumar Thada
Background: Cerebral venous thrombosis (CVT), a rare cause of stroke, primarily occurs in young individuals. The established treatment regimen involves anticoagulation with low molecular weight heparin (LMWH) and vitamin K antagonists (VKA). Although direct oral anticoagulants (DOACs) have emerged as a promising alternative, their efficacy and safety remain unclear. This meta-analysis compared the efficacy and safety of DOACs versus VKA in managing CVT. Methods: Electronic databases, including PubMed, Cochrane Library, and ScienceDirect, were searched from inception until April 2025. Risk ratios (RR) with a 95% Confidence interval (CI) were pooled under the random effects model in the Review Manager 5.4.1. Quality assessment was done through the Cochrane risk of bias (RoB 2.0) tool and the Newcastle Ottawa Scale (NOS). Subgroup analyses based on study design and different types of DOACs were carried out. Results: Thirty-one studies, including five randomized controlled trials (RCTs) and 26 observational studies, were included in this meta-analysis. Our analysis showed a significant reduction in the risk of recurrent venous thromboembolism (VTE) in the DOACs arm compared to VKA (RR = 0.84; 95%CI: [0.71,0.99]; p = 0.04; I 2 = 0%). Similarly, the DOACs showed significant superiority over VKA regarding the intracranial hemorrhage (ICH) (RR = 0.67; 95%CI: [0.50,0.89]; p = 0.007; I 2 = 0%). Other endpoints, including major hemorrhage (RR = 0.70; 95%CI:[0.42,1.15]; p = 0.16; I 2 = 0%), all-cause mortality (RR = 0.96; 95%CI:[0.68,1.35]; p = 0.81; I 2 = 0%), and full recanalization (RR = 0.92; 95%CI:[0.82,1.03]; p = 0.16; I 2 = 21%), are comparable between the two arms. Conclusion: DOACs showed a significant reduction in the risk of recurrent VTE and ICH compared to VKA, whereas other endpoints are comparable. Further RCTs with a robust sample size are required to validate and confirm these findings.

24 April 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
ASAreeba Shoaib
Areeba Shoaib
MOMuhammad Osama
Muhammad Osama
MAMuhammad Abdullah Ali
Muhammad Abdullah Ali
PTPawan Kumar Thada
Pawan Kumar Thada
Background: Intravenous thrombolytics are essential for achieving timely reperfusion in acute ischemic stroke (AIS), with alteplase historically serving as the standard of care. Emerging alternatives like recombinant human prourokinase (rhPro-UK), reteplase, and tenecteplase offer potential improvements in efficacy, safety, and convenience, necessitating a comparative analysis. Methods: Electronic databases, including PubMed, ScienceDirect, and Cochrane Central, were comprehensively searched from inception till December 2024 for relevant studies. A frequentist network meta-analysis was performed using R software version 4.2.3, and the “netmeta” package was employed. Alteplase 0.9 mg served as the reference group, with P-scores employed to determine the relative rankings of various interventions. The risk of publication bias was evaluated through funnel plots and Egger's regression test. Results: Eighteen trials with 12,950 participants were included in the final analysis. Compared to alteplase 0.9 mg, excellent functional outcome (mRS 0-1) was significantly improved by Reteplase 18 + 18 mg (RR = 1.13, p < 0.01) and Tenecteplase (TNK) 0.25 mg (RR = 1.05, p < 0.01). For a good functional outcome (mRS 0-2), Reteplase 18 + 18 mg (RR = 1.06, p < 0.01) and TNK 0.32 mg (RR = 1.30, p < 0.01) were significantly more effective than alteplase. Safety outcomes, symptomatic intracranial hemorrhage (sICH), and mortality were not significantly different between alteplase and other thrombolytics. According to P-scores, Reteplase 18 + 18 mg ranked the best for excellent functional outcome (P-score = 0.89) and TNK 0.32 mg for good functional outcome (P-score = 0.99), while rhPro-UK 35 mg ranked the best for sICH (P-score = 0.89). Conclusion: Reteplase 18 + 18 mg and TNK 0.32 mg demonstrated superior functional outcomes compared to alteplase, while rhPro-UK 35 mg showed the best safety profile with the lowest sICH risk.

1 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
JRJamir Pitton Rissardo
Jamir Pitton Rissardo
MKMuhammad Haris Khan
Muhammad Haris Khan
KFKanza Farhan
Kanza Farhan
ADAdam A. Dmytriw
Adam A. Dmytriw
Background: Cerebral venous thrombosis (CVT) is a rare but severe type of stroke, typically treated with vitamin K antagonists (VKAs). This study compares different direct oral anticoagulants (DOACs) with VKAs for the management of CVT. Methods: PubMed, Cochrane Central, and ScienceDirect were searched up to May 2025. A network meta-analysis using a frequentist approach was performed in RStudio version 4.3.3. P-scores were used to rank treatments. The evaluated outcomes included full recanalization, recurrent venous thromboembolism (VTE), major hemorrhage, intracranial hemorrhage (ICH), and mortality. The Cochrane Risk of Bias (RoB 2.0) tool and the Newcastle-Ottawa Scale (NOS) were employed to assess the quality of randomized controlled trials (RCTs) and observational studies. Results: Our analysis included 16 studies involving 1403 patients. We found that various DOACs, including apixaban, dabigatran, and rivaroxaban, had rates of full recanalization, VTE recurrence, major hemorrhage, ICH, and mortality comparable to those of VKAs. VKAs showed the highest likelihood of full recanalization, with a P-score of 0.70, whereas apixaban had the lowest, with a P-score of 0.04. For reducing recurrent VTE rates, apixaban was the most effective (P-score = 0.83), and dabigatran the least (P-score = 0.04). Apixaban also led to the greatest reduction in ICH risk (P-score = 0.70), while rivaroxaban had the lowest likelihood (P-score = 0.29). Regarding major hemorrhage, apixaban had the highest probability of reduction (P-score = 0.81), with VKAs performing worst (P-score = 0.26). Lastly, apixaban ranked highest for reducing mortality (P-score = 0.78), whereas VKAs ranked lowest (P-score = 0.39). Conclusion: DOACs showed no significant differences in rates of full recanalization, VTE recurrence, major hemorrhage, ICH, or mortality compared with VKAs. Apixaban had the highest probability of reducing VTE recurrence, mortality, and hemorrhagic events, whereas VKAs had the highest probability of achieving full recanalization.

14 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
DGDua Ghori
Dua Ghori
FSFaizan Shahzad
Faizan Shahzad
SKShamama Kaleem
Shamama Kaleem
BLBrandon Lucke-Wold
Brandon Lucke-Wold
Background: Stroke significantly impacts global health, and IV thrombolytics such as tenecteplase and alteplase are time sensitive. While they show promise beyond 4.5 h, evidence is inconclusive. This meta-analysis assesses IVT's efficacy and safety past 4.5 h. Methods: PubMed, Cochrane Central, and ScienceDirect were searched till August 2025. The risk ratios (RR) were pooled along with 95% confidence intervals under the random effect model using the Review Manager version 5.4.1. Results: Thirteen randomized trials involving 3602 patients were analyzed. Compared to the control group, IVT significantly improved the rates of excellent (RR = 1.22; 95%CI: [1.13, 1.31];p < 0.00001; I 2 = 0%) and good (RR = 1.11; 95%CI: [1.06, 1.18];p < 0.0001; I 2 = 0%) functional outcomes. However, the risk of symptomatic (RR = 2.28; 95%CI:[1.35, 3.85];p = 0.002; I 2 = 0%) and any (RR = 1.22; 95%CI:[1.01, 1.46];p = 0.04; I 2 = 13%) intracranial hemorrhage (ICH) was also higher with IVT; mortality rates, however, showed no significant difference (RR = 1.10; 95%CI:[0.89, 1.36];p = 0.35). TNK at 0.25 mg/kg did not improve functional outcomes or increase the risk of ICH. Similarly, low-dose 0.60 mg/kg alteplase did not significantly enhance functional outcomes or raise the risk of ICH, while alteplase at 0.90 mg/kg showed results consistent with the overall IVT group. Conclusion: IVT administered beyond the 4.5-h window in acute ischemic stroke significantly improved excellent and good functional outcomes. Although the use of IVT was associated with a higher risk of symptomatic and any ICH, the mortality rates remained comparable. Further high-quality randomized trials are necessary to confirm and reinforce these results.

1 September 2025 in Brain and Behavior
Verified
Journal Article
Open access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
NRNohela Rehman
Nohela Rehman
MKMuhammad Haris Khan
Muhammad Haris Khan
MTMuhammad Fawad Tahir
Muhammad Fawad Tahir
JIJaved Iqbal
Javed Iqbal
Background: Spontaneous supratentorial intracerebral hemorrhage (ICH) is a critical condition with high morbidity and mortality rates warranting urgent surgical evacuation. This systematic review and meta‐analysis compare the safety and efficacy of neuro‐endoscopy (NE) versus traditional craniotomy (CR) for managing ICH. Methods: From inception until July 2024, a comprehensive literature search was undertaken on PubMed, Cochrane Central, ScienceDirect, and Clinicaltrials.gov. Risk ratios (RR) and weighted mean differences (WMD) were pooled for categorical and continuous outcomes under the random effects model in Review Manager software. 5.4.1. Leave‐one‐out sensitivity analysis, Egger's regression, GRADE assessment, and meta‐regression were performed to evaluate the heterogeneity, publication bias, certainty of evidence, and effect size variability, respectively. Results: Our meta‐analysis included eight clinical trials and 20 cohort studies with 9,437 patients. NE outperformed CR in terms of favorable neurological outcomes (RR = 1.59, 95% CI: [1.30,1.94]; p < 0.00001; I 2 = 90%), mortality (RR = 0.62, 95% CI:[0.48,0.81]; p < 0.0004; I 2 = 51%), hematoma evacuation rate (WMD = 7.17, 95% CI: [4.68,9.65]%; p < 0.00001; I 2 = 94%) operating time (WMD = ‐102.08 min, 95 CI: [‐120.29,‐83.87]; p < 0.00001; I 2 = 98%), blood loss (WMD = ‐255.51 mL, 95% CI: [‐383.61,‐127.41]; p < 0.0001; I 2 = 100%), length of hospital stay (WMD = ‐3.34 days, 95% CI: [‐5.05,‐1.64] days; p < 0.0001; I 2 = 62%), ICU stay (WMD = ‐2.85, 95% CI: [‐5.13,‐0.57] days; p < 0.01; I 2 = 96%), meningitis (RR = 0.58, 95% CI: [0.36,0.95]; p < 0.03; I 2 = 10 %), infections (RR = 0.49, 95% CI: [0.35,0.67]; p < 0.0001; I 2 = 51%), residual hematoma volume (MD = ‐2.22; 95% CI: [‐3.37,‐1.07]; p < 0.0002; I 2 = 90%) and overall complications (RR = 0.52, 95% CI: [0.40‐0.67]; p < 0.00001; I 2 = 70%). In addition, re‐bleeding was found to be comparable between the CR and NE groups (p = 0.08). Conclusion: NE treatment for spontaneous intracerebral hemorrhage (ICH) is associated with favorable neurological outcomes, decreased mortality, shorter operating time, reduced blood loss and residual volume, shorter length of hospital and intensive care unit (ICU) stay, and fewer infections, meningitis, and overall complications; however, the re‐bleeding rate was found to be comparable.

1 August 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
ZAZain Ul Abideen
Zain Ul Abideen
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
NRNoor Ul Huda Ramzan
Noor Ul Huda Ramzan
HRHamna Raheel
Hamna Raheel
FHFariha Hasan
Fariha Hasan
PJPrasun K. Jalal
Prasun K. Jalal
Background: Portal venous thrombosis (PVT) is a serious complication in cirrhosis, with management debated due to differing anticoagulant guidelines. This network meta-analysis assessed various anticoagulants for PVT in cirrhotic patients. Methods: PubMed, Cochrane Central, and ScienceDirect were searched till May 2025. A frequentist network meta-analysis was conducted in RStudio version 4.3.3. The ranking was based on P-scores. Results: Nineteen studies were included in the analysis. Direct oral anticoagulants (DOACs) (RR = 2.38; 95%CI:[1.17, 4.85]; p = 0.02), fondaparinux (RR = 18.16; 95%CI:[2.09, 158.13]; p = 0.009), low-molecular-weight heparin (LMWH) (RR = 11.96; 95%CI:[1.58, 90.79]; p = 0.01), LMWH-Warfarin sequential therapy (RR = 2.32; 95%CI:[1.01, 5.31]; p = 0.04), and Vitamin K antagonists (VKA) (RR = 1.71; 95%CI:[1.03, 2.83]; p = 0.04) showed a significant increase in complete recanalization, with fondaparinux ranked highest (P-score = 0.94). DOACs (RR = 0.23;95%CI:[0.07, 0.71]; p = 0.01), LMWH (RR = 0.24;95%CI:[0.11, 0.52]; p = 0.0003), LMWH-Warfarin sequential therapy (RR = 0.40;95%CI:[0.21, 0.77]; p = 0.006) demonstrated a significant reduction in PVT progression, with Antithrombin-III ranked highest (P-score = 0.87). Fondaparinux was ranked highest (P-score = 0.90) for reducing esophageal variceal bleeding, while LMWH was ranked highest (P-score = 0.72) for decreasing overall bleeding. DOACs significantly decreased mortality (RR = 0.74; 95% CI: [0.67, 0.81]; p < 0.0001), with LMWH ranked highest (P-score = 0.80) for mortality. Conclusion: DOACs, LMWH, and LMWH-Warfarin sequential therapy significantly improved recanalization and reduced PVT progression. LMWH was ranked highest in reducing bleeding and mortality, while fondaparinux ranked highest regarding esophageal bleeding and complete recanalization.